Kalfa David, Vergnat Mathieu, Ly Mohamedou, Stos Bertrand, Lambert Virginie, Baruteau Alban, Belli Emre
Department of Pediatric and Congenital Heart Disease, Marie Lannelongue Hospital, University Paris Sud, Centre de Référence Nationale des Malformations Cardiaques Congénitales Complexes, "M3C," Le Plessis-Robinson, France.
Department of Pediatric and Congenital Heart Disease, Marie Lannelongue Hospital, University Paris Sud, Centre de Référence Nationale des Malformations Cardiaques Congénitales Complexes, "M3C," Le Plessis-Robinson, France.
J Thorac Cardiovasc Surg. 2014 Oct;148(4):1459-66. doi: 10.1016/j.jtcvs.2014.02.057. Epub 2014 Feb 26.
Surgical management of mitral regurgitation (MR) in children remains a challenge because of the heterogeneity of the anatomy, growth potential, and necessity to avoid valve replacement. Our objective was to assess the functional outcomes and prognostic factors of a standardized strategy of mitral valve (MV) repair for children with MR.
Consecutive patients aged <18 years who had undergone surgery for severe MR from 2001 to 2012 were studied retrospectively. The standardized repair strategy mainly included leaflet debridement, annuloplasty, and leaflet augmentation. Multivariable risk analyses for recurrent MR (grade>II), transmitral mean echocardiographic gradient>5 mm Hg, MV reoperation, replacement, and mortality were performed.
A total of 106 patients were included (median age, 5.1 years; range, 11 days to 18 years). The mean follow-up period was 3.9±3.2 years (range, 2 months to 11 years). The proportion of congenital and left heart obstruction-related (left ventricular outflow tract obstruction) etiology was 49% (n=52) and 11% (n=12), respectively. MV repair was performed primarily in 97% of the patients. The mortality, reoperation, replacement, and MR rate at the last follow-up visit was 4.5% (n=5), 23% (n=24), 5.5% (n=6), and 17% (n=18), respectively. Actuarial survival was 93%±2% at 10 years. Freedom from MV replacement was 95%±2% and 86%±7% at 5 and 15 years, respectively. Native valve preservation was obtained in 85% of the infants and 94% beyond infancy. Independent predictors of recurrent MR, MV reoperation, and replacement included left ventricular outflow tract obstruction etiology (hazard ratio, 45; P=.004), associated preoperative mitral stenosis (hazard ratio, 21; P=.03), and young age (hazard ratio, 1.2; P=.04).
A standardized and reproducible MV repair strategy can achieve satisfactory functional results in infants and children with severe MR, allowing native valve preservation. The left ventricular outflow tract obstruction-related etiology was the main independent predictor of recurrent MR, MV reoperation, and MV replacement.
由于二尖瓣反流(MR)患儿的解剖结构存在异质性、具有生长潜力且需避免瓣膜置换,因此其外科治疗仍是一项挑战。我们的目的是评估针对患有MR的儿童采用标准化二尖瓣(MV)修复策略的功能结局和预后因素。
对2001年至2012年期间接受严重MR手术的18岁以下连续患者进行回顾性研究。标准化修复策略主要包括瓣叶清创、瓣环成形术和瓣叶扩大术。对复发性MR(分级>II)、经二尖瓣平均超声心动图梯度>5 mmHg、MV再次手术、置换及死亡率进行多变量风险分析。
共纳入106例患者(中位年龄5.1岁;范围11天至18岁)。平均随访期为3.9±3.2年(范围2个月至11年)。先天性病因和左心梗阻相关(左心室流出道梗阻)病因的比例分别为49%(n = 52)和11%(n = 12)。97%的患者主要进行了MV修复。末次随访时的死亡率、再次手术率、置换率和MR发生率分别为4.5%(n = 5)、23%(n = 24)、5.5%(n = 6)和17%(n = 18)。10年时的精算生存率为93%±2%。5年和15年时无需MV置换的比例分别为95%±2%和86%±7%。85%的婴儿和94%的非婴儿患者实现了保留自身瓣膜。复发性MR、MV再次手术和置换的独立预测因素包括左心室流出道梗阻病因(风险比,45;P = 0.004)、术前合并二尖瓣狭窄(风险比,21;P = 0.03)和年龄较小(风险比,1.2;P = 0.04)。
标准化且可重复的MV修复策略可在患有严重MR的婴幼儿和儿童中取得令人满意的功能结果,实现保留自身瓣膜。左心室流出道梗阻相关病因是复发性MR、MV再次手术和MV置换的主要独立预测因素。